Hong Kong · Sponsored
Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker Assessment
This content is sponsored. It is intended for healthcare professionals only.
Due to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-10
